Brian Culley, CEO, and Brandi Roberts, CFO of Lineage Cell Therapeutics, Inc. (NYSE AMERICAN: LCTX), a leading publicly traded cell therapy and transplant company with in-house manufacturing and 3 clinical programs with billion dollar opportunities, will be presenting to investors on November 5, 2020 at the GCFF Virtual Conference – Diversified Investing Strategies.
The Company’s clinical-stage programs are based on one of the largest and most comprehensive patent estates in cell therapy:
Brian and Brandi are part of a dynamic management team that is committed to making the promise of cell therapy a reality; they have done a lot of work over the last 2 years to set Lineage up as a leading cell therapy company. We hope you are able to join our presentation on November 5th!
Brian M. Culley, B.S., M.B.A., CEO
Mr. Culley joined Lineage as CEO in September 2018. Prior to joining Lineage, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he was responsible for the management of the company. Mr. Culley previously served as Chief Executive Officer of Mast Therapeutics, Inc. (“Mast”), from February 2010, and was also a member of its Board of Directors from December 2011, until Mast’s merger with Savara, Inc. in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has more than 25 years of business and scientific experience in the life sciences industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.